Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research report released on Monday morning, Benzinga reports. The firm currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

Related Keywords

George Magrath ,Ocuphire Pharma ,Richmond Brothers Inc ,Vanguard Group Inc ,Ocuphire Pharma Company Profile ,Alliance Global Partners ,Nasdaq ,Kestra Private Wealth Services ,Ocuphire Pharma Inc ,Acadian Asset Management ,Free Report ,Get Free Report ,Private Wealth Services ,Asset Management ,Empowered Funds ,Phentolamine Ophthalmic Solution ,Ocuphire Pharma Daily ,